Form 4: Galectin CEO Sells Shares Under 10b5-1 Plan

Galectin Therapeutics Inc. CEO Joel Lewis executed planned sales of common stock, realizing significant gains from option exercises.

Summary

• Joel Lewis, President and CEO of Galectin Therapeutics Inc. (GALT), reported transactions involving the company's common stock.
• Transactions occurred on November 3, 2025, and November 4, 2025.
• These transactions were executed under a Rule 10b5-1 plan adopted on April 17, 2025, as previously disclosed in the company's Form 10-Q filed on August 14, 2025.
• On November 3, 2025, Lewis exercised options for 1,300 shares at an exercise price of $2.39 per share and simultaneously sold 1,300 shares at a weighted average price of $6.01.
• On November 4, 2025, Lewis exercised options for 14,420 shares at an exercise price of $2.39 per share and simultaneously sold 14,420 shares at a weighted average price of $6.07.
• The stock options exercised vested 100% on December 14, 2018, and are set to expire on December 14, 2027.
• Following these transactions, Lewis directly beneficially owns 832,592 shares of common stock and 24,530 derivative securities (stock options).
• Lewis also indirectly holds 2,000 shares as a USTA custodian for a minor child, for which beneficial ownership is disclaimed.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can sometimes be viewed negatively, the execution under a pre-arranged 10b5-1 plan mitigates concerns about opportunistic selling. The significant profit realized by the CEO is a positive for the individual but does not directly impact company sentiment.

Positives

• The CEO realized significant gains from the sale of shares, with sale prices ($6.01 and $6.07) substantially higher than the exercise price ($2.39).
• The transactions were conducted under a pre-arranged Rule 10b5-1 plan, indicating planned rather than opportunistic selling.

Negatives

• Insider selling, even if planned, can sometimes be perceived neutrally to slightly negatively by the market, as it reduces the insider's direct equity stake.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer’s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.
• The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
• The Reporting Person disclaims beneficial ownership of these securities [2,000 shares held as USTA custodian for a minor child], and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purpose of Section 16 or for any other purpose.

Industry Context

This filing, a routine insider transaction report, does not provide specific details to analyze broader industry trends or competitive landscape. It primarily reflects an individual executive's pre-planned equity management.

Stakeholder Impact

• Shareholders: The sale of shares by the CEO, even under a 10b5-1 plan, could lead to minor concerns about insider confidence, though the pre-planned nature reduces this impact. The transactions demonstrate the CEO's ability to monetize vested options at a profit.

Next Steps

• The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

Key Dates

Recommendation

The filing details routine insider transactions executed under a pre-arranged 10b5-1 plan. While the CEO is selling shares, this is a planned event and not necessarily indicative of a change in the company's fundamental outlook or the CEO's long-term confidence. The significant profit realized by the CEO from option exercises is notable. Without additional financial or operational context from other filings, a 'hold' recommendation is appropriate, as this Form 4 alone does not provide sufficient new information to warrant a change in investment thesis.

Keywords

Galectin Therapeutics, GALT, Joel Lewis, Insider Trading, Form 4, Stock Options, 10b5-1 Plan, CEO, Equity Sales